April 7, 2021
Grifols advances in the execution of its expansion plan with the acquisition of 7 plasma centers in the U.S.
- The seven plasma centers acquired from Kedrion obtain roughly 240,000 liters of plasma per year. The USD 55 million transaction will be financed with Grifols’ own resources.
- Grifols’ acquisitions of plasma centers in 2021 provide the company with immediate access to approximately 1.4 million liters per year and move forward with the execution of its plasma expansion plan.
- This transaction is aligned with the plasma-supply expansion and diversification strategy of the company, an industry leader with the world’s largest network of plasma centers: 351 centers in the U.S. and Europe.
- The company remains firmly committed to further increasing its plasma supply to meet current and expected strong increases in demand for plasma-based therapies.
Barcelona, April 7, 2021.- Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people’s health and well-being, closed the acquisition of seven U.S. plasma donation centers from Kedrion for USD 55.2 million. The operation received regulatory clearances and will be financed with Grifols’ own resources, without issuing debt.
Grifols will gain immediate access to the plasma obtained in these centers, which obtain approximately 240,000 liters per year. The seven newly acquired centers are authorized by the U.S. Food and Drug Administration (FDA) and European healthcare authorities.
This acquisition reflects Grifols’ commitment to enlarge its plasma supply through organic and inorganic growth.
Since January 2021, Grifols’ efforts to accelerate the execution of its strategic expansion plan have enabled it to instantly leverage approximately 1.4 million more liters of plasma yearly. At the same time, the company continues its efforts to open new centers.
In this regard, in March 2021, Grifols acquired 25 plasma centers from BPL Inc., which obtain approximately 1 million liters of plasma per year.
As part of its organic efforts, the company plans on opening between 15 and 20 new plasma centers in 2021. Additionally, Grifols will open several plasma centers in Egypt during the year1, following the strategic alliance signed with the Egyptian government in November 2020.
This most recent acquisition advances Grifols’ strategy to reinforce and diversify its access to plasma. An industry leader, the company boasts a robust network of 351 plasma centers, with 296 in the United States and 55 in Europe across Germany, Austria and, recently Hungary.
The transaction reinforces the company’s efforts to strengthen its plasma center network, which represents a significant competitive advantage. Grifols remains committed to increasing the availability of its life-enhancing plasma-derived products for patients who need them and doing its utmost to respond to expected strong demand.
Grifols retained the legal services of Osborne Clarke S.L.P. for this transaction.